Literature DB >> 21159010

Antiarrhythmic effects of losartan and enalapril in canine pulmonary vein sleeve preparations.

Serge Sicouri1, Jonathan M Cordeiro, Michael Talarico, Charles Antzelevitch.   

Abstract

INTRODUCTION: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II-receptor blockers (ARBs) are prototypes of "upstream" therapy for the management of atrial fibrillation (AF). Ectopic activity arising from the PV sleeves plays a prominent role in the development of AF.
METHODS: Transmembrane action potentials were recorded from canine superfused left superior or inferior PV sleeves using standard microelectrode techniques. Acetylcholine (ACh, 1 μM), isoproterenol (1 μM), high calcium ([Ca(2+)](o) = 5.4 mM) or a combination was used to induce early or delayed afterdepolarizations (EADs or DADs) and triggered activity.
RESULTS: The ARB losartan (1 μM, n = 5) and the ACE inhibitor enalapril (10 μM, n = 5) produced no significant change in action potential duration, maximum rate of rise of action potential upstroke (V(max)), action potential amplitude or take-off potential at basic cycle lengths of 200 to 2000 ms. Losartan (1 μM) and enalapril (10-20 μM) markedly attenuated or suppressed EADs and DAD-induced triggered activity elicited by exposure of the PV sleeves to ACh, isoproterenol or high calcium following rapid pacing in 6 of 6 (losartan) and 4 of 5 (enalapril) PV sleeve preparations. Neither losartan nor enalapril altered Ca(2+) or K(+) channel currents in enzymatically-dissociated atrial myocytes at these concentrations.
CONCLUSIONS: Our data suggest that in addition to their "upstream" effects to reduce atrial structural remodeling, ACE inhibitors and ARBs exert a "direct" antiarrhythmic effect by suppressing triggers responsible for the genesis of AF and other atrial arrhythmias.
© 2010 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21159010      PMCID: PMC3061245          DOI: 10.1111/j.1540-8167.2010.01972.x

Source DB:  PubMed          Journal:  J Cardiovasc Electrophysiol        ISSN: 1045-3873


  28 in total

1.  Atrial fibrillation: an epidemiologic, scientific and clinical challenge.

Authors:  Valentin Fuster
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2005-05

2.  Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation.

Authors:  Yuehui Yin; Darshan Dalal; Zengchang Liu; Jinjin Wu; Dong Liu; Xianbin Lan; Yin Dai; Li Su; Zhiyu Ling; Qiang She; Kailiang Luo; Kamsang Woo; Jun Dong
Journal:  Eur Heart J       Date:  2006-07-06       Impact factor: 29.983

3.  Triggered firing in pulmonary veins initiated by in vitro autonomic nerve stimulation.

Authors:  Eugene Patterson; Sunny S Po; Benjamin J Scherlag; Ralph Lazzara
Journal:  Heart Rhythm       Date:  2005-06       Impact factor: 6.343

4.  Arrhythmogenic activity of cardiac muscle in pulmonary veins of the dog: implication for the genesis of atrial fibrillation.

Authors:  Y J Chen; S A Chen; M S Chang; C I Lin
Journal:  Cardiovasc Res       Date:  2000-11       Impact factor: 10.787

5.  Antiarrhythmic effects of losartan and enalapril in canine pulmonary vein sleeve preparations.

Authors:  Serge Sicouri; Jonathan M Cordeiro; Michael Talarico; Charles Antzelevitch
Journal:  J Cardiovasc Electrophysiol       Date:  2010-12-16

Review 6.  Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence.

Authors:  Joachim R Ehrlich; Stefan H Hohnloser; Stanley Nattel
Journal:  Eur Heart J       Date:  2005-11-25       Impact factor: 29.983

7.  Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations.

Authors:  Serge Sicouri; Aaron Glass; Luiz Belardinelli; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2008-03-21       Impact factor: 6.343

8.  Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation.

Authors:  Felix Gramley; Johann Lorenzen; Jurgita Plisiene; Mindaugas Rakauskas; Rimantas Benetis; Michael Schmid; Rüdiger Autschbach; Christian Knackstedt; Thomas Schimpf; Karl Mischke; Axel Gressner; Peter Hanrath; Malte Kelm; Patrick Schauerte
Journal:  J Cardiovasc Electrophysiol       Date:  2007-07-26

9.  Calmodulin kinase II inhibition prevents arrhythmic activity induced by alpha and beta adrenergic agonists in rabbit pulmonary veins.

Authors:  Li-Wei Lo; Yao-Chang Chen; Yi-Jen Chen; Wanwarang Wongcharoen; Cheng-I Lin; Shih-Ann Chen
Journal:  Eur J Pharmacol       Date:  2007-06-13       Impact factor: 4.432

10.  Aging increases pulmonary veins arrhythmogenesis and susceptibility to calcium regulation agents.

Authors:  Wanwarang Wongcharoen; Yao-Chang Chen; Yi-Jen Chen; Szu-Ying Chen; Huang-I Yeh; Cheng-I Lin; Shih-Ann Chen
Journal:  Heart Rhythm       Date:  2007-08-17       Impact factor: 6.343

View more
  8 in total

1.  Electrophysiological characteristics of canine superior vena cava sleeve preparations: effect of ranolazine.

Authors:  Serge Sicouri; Jonathan Blazek; Luiz Belardinelli; Charles Antzelevitch
Journal:  Circ Arrhythm Electrophysiol       Date:  2012-03-09

2.  Antiarrhythmic effects of losartan and enalapril in canine pulmonary vein sleeve preparations.

Authors:  Serge Sicouri; Jonathan M Cordeiro; Michael Talarico; Charles Antzelevitch
Journal:  J Cardiovasc Electrophysiol       Date:  2010-12-16

3.  Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations.

Authors:  Serge Sicouri; Brittany Gianetti; Andrew C Zygmunt; Jonathan M Cordeiro; Charles Antzelevitch
Journal:  J Am Coll Cardiol       Date:  2011-02-22       Impact factor: 24.094

4.  Pulmonary Vein Sleeves as a Pharmacologic Model for the Study of Atrial Fibrillation.

Authors:  Serge Sicouri; Charles Antzelevitch
Journal:  Electrofisiol Arritm       Date:  2010-10

5.  Mechanisms involving Ang II and MAPK/ERK1/2 signaling pathways underlie cardiac and renal alterations during chronic undernutrition.

Authors:  Paulo A Silva; Gustavo Monnerat-Cahli; Amaury Pereira-Acácio; Ricardo Luzardo; Luzia S Sampaio; Marcia A Luna-Leite; Lucienne S Lara; Marcelo Einicker-Lamas; Rogério Panizzutti; Caroline Madeira; Leucio D Vieira-Filho; Carmen Castro-Chaves; Valdilene S Ribeiro; Ana D O Paixão; Emiliano Medei; Adalberto Vieyra
Journal:  PLoS One       Date:  2014-07-01       Impact factor: 3.240

6.  Pharmacologic Prevention of Incident Atrial Fibrillation: Long-Term Results From the ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial).

Authors:  Thomas A Dewland; Elsayed Z Soliman; Jose-Miguel Yamal; Barry R Davis; Alvaro Alonso; Christine M Albert; Lara M Simpson; L Julian Haywood; Gregory M Marcus
Journal:  Circ Arrhythm Electrophysiol       Date:  2017-12

7.  Routine versus aggressive upstream rhythm control for prevention of early atrial fibrillation in heart failure: background, aims and design of the RACE 3 study.

Authors:  M Alings; M D Smit; M L Moes; H J G M Crijns; J G P Tijssen; J Brügemann; H L Hillege; D A Lane; G Y H Lip; J R L M Smeets; R G Tieleman; R Tukkie; F F Willems; R A Vermond; D J Van Veldhuisen; I C Van Gelder
Journal:  Neth Heart J       Date:  2013-07       Impact factor: 2.380

Review 8.  Atrial fibrillation.

Authors:  Thomas M Munger; Li-Qun Wu; Win K Shen
Journal:  J Biomed Res       Date:  2013-12-28
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.